title: Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.
abstract: Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens. This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments. Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed. Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.
authors.affiliation: Laboratory of Biology and Treatment of Metastases, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri" , Milan , Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Cesca
authors.forename: Francesca
authors.initials: F
authors.lastname: Bizzaro
authors.forename: Massimo
authors.initials: M
authors.lastname: Zucchetti
authors.forename: Raffaella
authors.initials: R
authors.lastname: Giavazzi
keywords: angiogenesis inhibitors; combination therapies; drug delivery; paclitaxel; tumor microenvironment; tyrosine kinase receptor inhibitors; vascular disrupting agents